Silvercrest Asset Management Group LLC Ngm Biopharmaceuticals Inc Transaction History

Silvercrest Asset Management Group LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$12.59 - $17.67 $60,394 - $84,762	-4,797 Reduced 2.65%	176,125 $2.3 Million
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $85,518 - $141,452	-8,083 Reduced 4.28%	180,922 $2.32 Million
Q1 2022 May 16, 2022	BUY	$13.81 - $18.6 $24,333 - $32,773	1,762 Added 0.94%	189,005 $2.88 Million
Q3 2021 Nov 15, 2021	BUY	$20.15 - $26.19 $1.43 Million - $1.86 Million	70,981 Added 61.05%	187,243 $3.94 Million
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $932,515 - $1.86 Million	61,920 Added 113.95%	116,262 $2.29 Million
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $1.36 Million - $1.74 Million	54,342 New	54,342 $1.58 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Silvercrest Asset Management Group LLC, based on Form 13F filings with the SEC.

Stay updated on Silvercrest Asset Management Group LLC with notifications on news.